Commitments and contingencies (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Aug. 27, 2021 |
Sep. 06, 2018 |
Mar. 17, 2017 |
Jun. 30, 2021 |
Sep. 30, 2021 |
Jun. 30, 2020 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Loss Contingency, Lawsuit Filing Date | May 28, 2019 | |||||
| Description on trial dispute resolution | On November 13, 2019, G Farma filed a Cross-Complaint for declaratory relief and breach of contract relating to the consulting agreement between Mentor and G Farma. The Company filed an answer on December 6, 2019, denying each and every allegation of the Cross-Complaint and intends to vigorously defend itself in this matter. | |||||
| G Farma Labs Limited [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Business Acquisition, Equity Interest Issued or Issuable, Description | On March 4, 2019, Addendum VIII increased the G Farma Equity Entities’ equity interest to which Mentor is immediately entitled to 3.843%, and added Goya Ventures, LLC as a G Farma Equity Entity. | |||||
| G Farma Labs Limited [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Sale Leaseback Transaction, Net Book Value | $ 622,670 | |||||
| Loss Contingency, Receivable, Proceeds | $ 249,481 | |||||
| Notes Purchase Agreement [Member] | G Farma Labs Limited [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Purchase of secured promissory notes | $ 500,000 | |||||
| Increased aggregate principal face amount | 1,100,000 | |||||
| Notes Purchase Agreement [Member] | G Farma Labs Limited [Member] | Secured Promissory Notes [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Monthly payments | 10,239 | |||||
| Ballon payments on notes | $ 894,172 | |||||
| Equity Purchase and Issuance Agreement [Member] | G Farma Labs Limited [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Business Acquisition, Percentage of Voting Interests Acquired | 3.75% | |||||
| Settlement Agreement And Mutual Release [Member] | G Farma [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Contingent claim description | The Settlement Agreement requires the G Farma Entities to pay the Company an aggregate of $500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5 thereafter, until the settlement amount and accrued unpaid interest is paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25%, commencing February 25, 2021, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1%. | |||||
| Liability for Unpaid Claims and Claims Adjustment Expense, Net | $ 500,000 | |||||
| Additional outstanding claim | $ 2,000,000 |